3 results about "Enoxacin" patented technology

The invention belongs to the technical field of veterinary drugs, and discloses a preparation method and application of pH response type enrofloxacin granules for treating porcine respiratory bacterial mixed infection. The invention provides the enrofloxacin coated particle, the enrofloxacin coated particle has pH response capability, is not released in a stomach pH environment and can be quickly released in a near small intestine pH environment, so that the stomach irritation of enrofloxacin is reduced, and the enrofloxacin is ensured to be absorbed at an optimal part. According to the enrofloxacin coated granules, the bitter taste of the medicine is effectively covered, the administration frequency is reduced, and the effective plasma concentration maintaining time is prolonged. Meanwhile, the enrofloxacin coated granules have a good treatment effect on porcine respiratory diseases caused by mixed infection of various bacteria.

The invention belongs to the technical field of nano material detection, and particularly discloses a double-ligand lanthanide series metal organic framework Tb-MOF for rapidly detecting enoxacin and a rapid detection method for enoxacin concentration. According to the invention, 2, 6-pyridinedicarboxylic acid and 2-aminoterephthalic acid are used as modification ligands to construct Tb-MOF, and after enoxacin is added into a system of the Tb-MOF, the fluorescence intensity and fluorescence color of the Tb-MOF are subjected to characteristic change due to an antenna effect, so that the fluorescence colorimetric sensor is constructed. A portable detection device based on a smart phone is further designed, a cloud server data analysis system integrated with a machine learning algorithm is fused with the smart phone, and collection, correction, analysis and result display of fluorescence color data can be efficiently completed. According to the invention, the capturing and processing capability of a modern smart phone on fluorescence color signals is fully utilized, and a set of solution which is convenient to operate and user-friendly is provided for on-site detection of enoxacin.

A combination therapy comprising enoxacin, palbociclib, and fulvestrant is provided, along with a method for treating locally advanced or metastatic breast cancer with PIC3CA mutations, hormone receptor-positive (HR+), and HER2-negative (HER2-), the method comprising administering therapeutically effective amounts of enoxacin, palbociclib, and fulvestrant. The combination therapy produced statistically significant and clinically meaningful improvements in comparable patients compared to administration of palbociclib and fulvestrant alone.